IGF2BP3 and acute myeloid leukemia: Subsequently, the associations between IGF2BP3 expression and clinical parameters were assessed, and aberrantly high expression of IGF2BP3 in AML patients was significantly correlated with more unfavorable clinical characteristics on measures such as cytogenetic risk stratification (Fig. 1g), age (Fig. 1h), FAB (French-American-British) subtype (Fig. 1i) and molecular subtype (Fig. 1j).